Some patients with pulmonary arterial hypertension (PAH) are now able to access Actelion’s selexipag on the NHS in Wales after a green light from the All Wales Medicines Strategy Group (AWMSG).
Read More
The All Wales Medicines Strategy Group has approved NHS funding for the use of UCB’s Vimpat in children with epilepsy.
Read More
Pfizer’s Somavert will be funded by NHS Wales as a treatment for eligible, adult patients with acromegaly in the third-line setting.
Read More
A five-year, £80 million new treatment fund has now been launched in Wales in the hope of accelerating patient access to novel therapies.
Read More
Novo Nordisk’s long-acting insulin Tresiba has been approved for routine use by NHS Wales as an option for treating diabetes.
Read More
Around 300 patients with multiple myeloma in Wales will get National Health Service access to treatment with Celgene’s Revlimid after the drug was recommended for first-line use by cost regulators.
Read More
A new £80 million fund designed to help accelerate access to treatments for patients with life-threatening illnesses in Wales has now been confirmed by the Welsh government.
Read More
Eli Lilly’s once-weekly diabetes drug Trulicity (dulaglutide) has been recommend for restricted routine use on NHS Wales.
Read More
